MAY 2025 | ANALYST REPORT | More Medicare Reimbursement Coverage Secured for FebriDx
7 May 2025
MST Access Senior Analyst Chris Kallos has released an updated report on Lumos Diagnostics, maintaining a valuation of A$0.10 per share and highlighting our significant progress with FebriDx® Medicare reimbursement coverage in the United States.
Here's an excerpt:
"LDX is advancing its commercialisation strategy by expanding its flagship FebriDx® test into global markets, broader clinical settings in the US and extend its labelling to paediatric populations. Strategic partnerships and regulatory approvals will be key drivers of revenue scalability and long-term profitability in the diagnostics sector."
Click to read the full report
Here's an excerpt:
"LDX is advancing its commercialisation strategy by expanding its flagship FebriDx® test into global markets, broader clinical settings in the US and extend its labelling to paediatric populations. Strategic partnerships and regulatory approvals will be key drivers of revenue scalability and long-term profitability in the diagnostics sector."
Click to read the full report
